Aug 21, 2023Inflection Biosciences Announces Licensing of PIM kinase Inhibitors to Mysthera TherapeuticsDublin, Ireland, August 21 2023 Inflection Biosciences (Inflection), a company developing innovative therapeutics for the treatment of...
Dec 5, 2022Inflection Biosciences Announces Pre-clinical data for IBL-101 to be Presented at BSI Congress 2022Dublin, Ireland, December 5, 2022 Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer,...
May 30, 2022Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial IntelligenceESCHBORN, Germany, May 30, 2022 Innoplexus, a global leader in AI-based drug discovery and development, and Inflection Biosciences Ltd.,...
May 27, 2022Inflection Biosciences Announces Expansion of Research into Autoimmune and Inflammatory Disease Expands Advisory Panel with Immunology and Rheumatology Expertise Dublin, Ireland, May 27, 2022 Inflection Biosciences Ltd, a company...
Nov 11, 2021Inflection Biosciences Announces Publication on Discovery of AUM302 in ACS Medicinal ChemistryDublin, Ireland, November 10, 2021 Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer,...
Oct 23, 2020Inflection Biosciences Announces Publication of Positive Pre-clinical Data for IBL-202 in CLL.Dublin, Ireland, October 23, 2020 Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer,...